NEWSROOM
Discover all the actions carried out by Jeito and all the partnerships that we set up day after day for the well-being of patients and medical progress.
In the headlines
Jeito Capital consolidates its support in CatalYm with a renewed participation in a $150 million financing
This new financing will support broad late-stage clinical development program for visugromab, CatalYm’s lead product candidate in cancer immunotherapy. After a first investment as co-lead investor in CatalYm’s €50 million series C financing (November 2022), Jeito’s...
Find all our press releases
Jeito Capital announces the acquisition by Merck & Co (NYSE: MRK) of its portfolio company EyeBio for a potential value of $3 billion
This acquisition reflects the significant clinical progress achieved with Restoret™,EyeBio’s novel...
Jeito Capital announces acquisition of portfolio company HI-Bio™ by Biogen Inc. (Nasdaq: BIIB) for up to $1.8 billion; Biogen to strengthen portfolio to help patients with severe immune-mediated disease
Biogen Inc. (Nasdaq: BIIB) to acquire HI-Bio™ for a total consideration of up to $1.8 billion...
Jeito Capital strengthens its Executive Committee with the appointment of Sarah Leroy who is taking the newly created position of Secretary General responsible for managing Legal and Financial Affairs, Compliance, HR and Sustainability
Paris, France, March 14th 2024 - Jeito Capital ("Jeito"), a global leading independent private...
EyeBio Announces Positive Visual, Anatomic and Safety Data from First-in-Human Ph1b/2a AMARONE Trial of Restoret at Macula Society Annual Meeting
Twelve week data from the Ph1b/2a AMARONE trial reveals Restoret to be well-tolerated in patients...
Jeito Capital participates in a $95 Million financing for HI-Bio™, a US-based clinical-stage biopharma company developing targeted therapies for patients with severe immune-mediated diseases
One year after its first investment, this new significant participation in HI-Bio™’s Series B...
Jeito Capital portfolio company Advesya emerges from stealth mode with the potential to become a leader in the treatment of hematological malignancies and other tumor treatments
Paris, France, 3 January 2024 - Jeito Capital ("Jeito"), a global leading independent private...
Face to face
Meet Jeito
9-11
September
All day long
IPEM Paris 2024
Jeito will be present at IPEM, the International Private Equity Market, an international forum bringing together the major players in Private Equity, in Paris, France.
25-26
September
All day long
Invest Europe – Venture Capital Forum 2024
Jeito will be present at the Venture Capital Forum 2024 of Invest Europe, a leading European conference for LPs and GPs engaged in VC activity, in Amsterdam, Netherlands. Dr Rafaèle Tordjman, Founder & CEO of Jeito Capital, will be sharing her views as a speaker on the conference “Maximising Exit Strategies” on the 26th of September from 4pm to 4.45pm.